Power3 Medical Products Exhibiting at the 4th Drug Discovery for Neurodegeneration Conference in Houston Feb. 2010

HOUSTON, Jan. 20, 2010 (GLOBE NEWSWIRE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) is pleased to announce that the company will be a sponsor and have an exhibit booth at the 4th Annual Conference of the Alzheimer's Drug Discovery Foundation on Drug Discovery for Neurodegeneration in Houston on February 1-2, 2010.

“This meeting is particularly appropriate for the company. The NuroPro® blood protein biomarkers and tests for early detection, differential diagnosis, and monitoring of therapeutic response of Alzheimer’s disease, Parkinson’s disease and ALS are progressing through clinical validation trials,” said Dr. Ira L. Goldknopf, Chief Scientific Officer. “Power3 remains at the forefront of this area.” 

 “I am proud of the continued progress of Power3 in the neurodegenerative diseases. We are continuing publication and promotion of the exciting results of our clinical validation trials in these areas and are glad to have the opportunity to move into the marketing area of drug discovery,” said Helen R. Park, CEO of Power3 Medical. “We are eager to make an impact in drug discovery for neurodegenerative disease and think our presence at this conference will provide inroads into that area.”

About Power3 Medical Products, Inc.

Power3 Medical Products, http://www.Power3Medical.com, is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer's, and Parkinson's diseases, breast cancer, and drug resistance.

For more information visit, http://www.Power3Medical.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements and/or Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.


Contact Data